Aimmune Therapeutics Inc (NASDAQ:AIMT) – Equities research analysts at Piper Jaffray Companies upped their Q2 2019 earnings per share (EPS) estimates for Aimmune Therapeutics in a note issued to investors on Wednesday, May 8th. Piper Jaffray Companies analyst C. Raymond now anticipates that the biotechnology company will earn ($0.90) per share for the quarter, up from their previous estimate of ($0.92). Piper Jaffray Companies also issued estimates for Aimmune Therapeutics’ Q3 2019 earnings at ($0.92) EPS, Q4 2019 earnings at ($0.94) EPS, FY2019 earnings at ($3.64) EPS, Q1 2020 earnings at ($0.83) EPS, Q2 2020 earnings at ($0.76) EPS, Q3 2020 earnings at ($0.61) EPS, Q4 2020 earnings at ($0.36) EPS, FY2020 earnings at ($2.56) EPS, FY2021 earnings at ($0.33) EPS and FY2022 earnings at $2.71 EPS.
Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings data on Thursday, February 28th. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.11).
Shares of NASDAQ:AIMT opened at $20.11 on Monday. Aimmune Therapeutics has a 12-month low of $19.25 and a 12-month high of $36.12. The company has a market cap of $1.28 billion, a PE ratio of -5.48 and a beta of -0.20.
Institutional investors and hedge funds have recently made changes to their positions in the business. Cable Hill Partners LLC raised its position in Aimmune Therapeutics by 81.7% during the first quarter. Cable Hill Partners LLC now owns 1,112 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 500 shares in the last quarter. Manchester Capital Management LLC acquired a new position in Aimmune Therapeutics during the first quarter valued at approximately $27,000. Carroll Financial Associates Inc. acquired a new position in Aimmune Therapeutics during the fourth quarter valued at approximately $28,000. Pearl River Capital LLC acquired a new position in Aimmune Therapeutics during the first quarter valued at approximately $28,000. Finally, Bank of Montreal Can raised its position in Aimmune Therapeutics by 47.9% during the fourth quarter. Bank of Montreal Can now owns 1,516 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 491 shares in the last quarter. Institutional investors and hedge funds own 73.66% of the company’s stock.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
See Also: What are the FAANG Stocks?
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.